Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-20/19-T Cells in Relapsed/Refractory B-Cell Malignancies
NCT03019055Phase 1Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Oct 2017
- Primary completion
- Oct 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zamtocabtagene autoleucel in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Medical College of Wisconsin. Primary endpoint: Number of Adverse Events After CAR 20/19-T Cell Infusion at 28 days. Started Oct 2017; status: completed.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03019055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019055.